B
Bull
Bull · 25%SOPH
$4.36
Precio del escenario
$8.140
-0.711 (-8.74%)Al cierre
Loading chart…
- High
- 8.910
- Open
- 8.800
- VWAP
- 8.37
- Vol
- 417.17K
- Mkt Cap
- 303.34M
- Low
- 8.060
- Amount
- 3.49M
- EV/EBITDA, TTM
- -7.79
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide.
AI analysis of Sophia Genetics SA (SOPH)
buySOPHiA Genetics (SOPH) is a good buy right now due to its strong revenue growth of 27% year-over-year in Q2 2026, with projected full-year revenue guidance raised to between $94 million and $96 million. Additionally, the stock has experienced a remarkable 74.30% year-to-date increase, reflecting strong investor confidence. The main risk is the negative earnings per share of -0.30 reported in Q2, which indicates ongoing financial challenges that investors should monitor closely.
Métricas de valoración
The current forward P/E ratio for Sophia Genetics SA (SOPH) is 0.00, compared to its 5-year average forward P/E of -4.45.
Alphio AI Price Scenarios for SOPH
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SOPH
Cronología de eventos
Noticias
2.008-11NASDAQ.COMSOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript
2.008-05NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Key Catalysts
8.508-04stocktwitsSophia Genetics to Develop Cancer Diagnostic Tests
9.508-04seekingalphaSOPHiA Genetics Q2 Earnings Beat Expectations with Revenue Growth
9.508-04PRnewswireSOPHiA GENETICS Reports Strong Q2 Results with 27% Revenue Growth
SOPH FAQ — answered by Alphio AI
SOPHiA GENETICS SA is a Switzerland-based company primarily engaged in the healthcare technology industry. The Company’s key product is SOPHiA DDM, which is a cloud-native software-as-a-service (SaaS) platform. The platform analyses multimodal data, including genomics, radiomics, clinical, biological, and digital pathology data, to generate actionable insights for patients with cancer or rare diseases, bringing the power of data-driven medicine to patients across the globe. Additionally, the Company aids BioPharma partners with artificial-intelligence-powered drug discovery, development, and deployment. The Company has offices in Switzerland, France, and the United States and operates worldwide. It operates in the Healthcare sector.
SOPHiA Genetics (SOPH) is a good buy right now due to its strong revenue growth of 27% year-over-year in Q2 2026, with projected full-year revenue guidance raised to between $94 million and $96 million. Additionally, the stock has experienced a remarkable 74.30% year-to-date increase, reflecting strong investor confidence. The main risk is the negative earnings per share of -0.30 reported in Q2, which indicates ongoing financial challenges that investors should monitor closely.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.